Veracyte, Inc. (NASDAQ:VCYT - Free Report) - William Blair raised their Q2 2025 earnings estimates for shares of Veracyte in a research report issued to clients and investors on Tuesday, May 13th. William Blair analyst A. Brackmann now expects that the biotechnology company will post earnings of $0.19 per share for the quarter, up from their previous forecast of $0.18. The consensus estimate for Veracyte's current full-year earnings is $0.68 per share. William Blair also issued estimates for Veracyte's Q3 2025 earnings at $0.19 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.31 EPS and FY2026 earnings at $0.88 EPS.
Veracyte (NASDAQ:VCYT - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.07. The company had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. During the same period in the previous year, the business posted ($0.39) EPS.
VCYT has been the topic of a number of other reports. StockNews.com downgraded shares of Veracyte from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. UBS Group reduced their price target on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reduced their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Stephens reissued an "overweight" rating and issued a $45.00 price target on shares of Veracyte in a research note on Wednesday, March 26th. Finally, Guggenheim cut their target price on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.90.
View Our Latest Analysis on VCYT
Veracyte Stock Performance
Shares of Veracyte stock traded down $0.20 on Friday, reaching $29.00. The company had a trading volume of 649,019 shares, compared to its average volume of 890,093. The firm's 50 day moving average price is $30.75 and its two-hundred day moving average price is $36.95. The firm has a market cap of $2.27 billion, a PE ratio of -193.33 and a beta of 2.14. Veracyte has a 52-week low of $19.73 and a 52-week high of $47.32.
Institutional Investors Weigh In On Veracyte
A number of large investors have recently modified their holdings of VCYT. Artisan Partners Limited Partnership increased its position in shares of Veracyte by 31.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 6,599,264 shares of the biotechnology company's stock valued at $261,331,000 after purchasing an additional 1,576,432 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Veracyte in the 1st quarter valued at approximately $33,003,000. Marshall Wace LLP increased its position in shares of Veracyte by 768.9% in the 4th quarter. Marshall Wace LLP now owns 956,577 shares of the biotechnology company's stock valued at $37,880,000 after purchasing an additional 846,487 shares during the last quarter. Driehaus Capital Management LLC increased its position in shares of Veracyte by 226.8% in the 4th quarter. Driehaus Capital Management LLC now owns 1,183,766 shares of the biotechnology company's stock valued at $46,877,000 after purchasing an additional 821,554 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Veracyte in the 4th quarter valued at approximately $20,717,000.
Veracyte Company Profile
(
Get Free Report)
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Further Reading
Before you consider Veracyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.
While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
